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a b s t r a c t
Mass spectrometry-based (clinical) proteomics has been widely applied as a technology
to ﬁnd and validate disease-speciﬁc protein signatures. MALDI-based peptidome proﬁles
provide a suitable platform for classiﬁcation of body ﬂuids or tissues, albeit at the cost
of being unable to observe low abundant species. Here we show that a fully automated
one-step solid-phase extraction serum sample cleanup in combination with fast MALDI
acquisition and ultrahigh precision 15T FTICR readout provides a powerful, fast and robust
approach for obtaining biomarker signatures. This is exempliﬁed for a cohort of pancre-
atic cancer patients. Speciﬁc “early cancer” symptoms such as pain, jaundice or weight
loss are often not experienced, thus delaying diagnosis of the disease. Novel markers for
early diagnosis of pancreatic cancer are therefore urgently needed. A total of 273 serum
samples, distributed over a calibration and validation set, were processed and mass ana-
lyzed within a time frame of 24h. In both sets sensitivity and selectivity values were wellabove 85%. In these “next-generation” MALDI peptidome proﬁles all species up to 9kDa
were isotopically resolved. Finally, it is noted that the low ppm mass accuracy of pep-
tides and proteins observed between 1 and 9kDa in the FTICR proﬁles facilitates sequence
identiﬁcations.
The Open access under CC BY-NC-SA license.© 2013
. Introductionancreatic cancer (PC) is the fourth (females) and ﬁfth (males)
eading cause of cancer death in developed countries, with
relatively low annual incidence of 5.4 cases per 100,000
∗ Corresponding author at: Leiden University Medical Center, Center for
etherlands. Tel.: +31 71 526 5062.
E-mail address: y.e.m.van der burgt@lumc.nl (Y.E.M. van der Burgt).
1 These authors contributed equally to this study.
212-9634 © 2013 The Authors. Published by Elsevier B.V.
ttp://dx.doi.org/10.1016/j.trprot.2013.12.003
Open access underAuthors. Published by Elsevier B.V.
females and 8.2 cases per 100,000 males [1]. Patients often
die within the ﬁrst half year after diagnosis, or have anProteomics and Metabolomics, P.O. Box 9600, 2300 RC Leiden, The
extremely poor prognosis with an overall ﬁve-year survival
rate of less than 5% [2]. When surgical resection is possi-
ble, ﬁve-year survival rates improve to approximately 25%.
Unfortunately, when the ﬁrst symptoms appear most tumors
 CC BY-NC-SA license.
teom40 translat ional pro
are at an advanced stage and their surgical resection would
not improve the prognosis [3,4]. Molecular biomarkers that
detect PC at an early stage with high sensitivity and speci-
ﬁcity would thus be highly beneﬁcial. At the moment, the
only used blood marker for detecting and following PC in the
clinic is the mucin-associated carbohydrate antigen CA 19-9.
Thismarker, however, often fails in detecting small, resectable
cancers [5]. Consequently, like in other cancer biomarker stud-
ies, serum proteomics has become a popular approach to ﬁnd
new markers for PC, since blood is a rich and powerful source
of biomarkers in general and samples can be collected in a
minimally invasive way. The discovery of serum biomarkers
is mainly performed by mass spectrometry (MS)-based pro-
teomics methods [6]. One of these involves the comparison
of serum protein proﬁles in a “case versus control” manner
by matrix-assisted laser desorption/ionization – time of ﬂight
(MALDI-TOF) MS [7]. Such proﬁles (i.e. mass spectra) con-
tain hundreds of features (or peaks), of which the presence
and intensity can depend on the physiological and patho-
logical condition of the individual. The statistical analysis of
serum peptide and protein proﬁles obtained from both con-
trol and diseased individuals allows the identiﬁcation of a set
of features, or a so-called biomarker signature, that can be
valuable in understanding the speciﬁc disease. Moreover, the
biomarker signature may provide leads to further exploit diag-
nostic and therapeutic potential. Encouraging results have
been obtained using proﬁling strategies [8–10]. Nevertheless,
the route to clinically applicable protein assays faces vari-
ous types of challenges [11,12]. With regard to the selected
methodology, for MS-based peptide proﬁling approaches the
problems can be categorized as follows. First of all, multi-
ple proﬁling studies have shown to lack reproducibility and
could not be validated. In this context, standardization of
the protocols used for serum sample collection and for pep-
tide and protein puriﬁcation is pivotal [10,13,14]. The use
of a fully automated high-throughput platform for sample
processing based on solid-phase extraction (SPE) has been
shown to minimize variation and to improve robustness of
the method [15]. Secondly, previous MS-acquisitions such as
performed on surface-enhanced laser desorption/ionization
(SELDI) platformswere not robust and yielded poor accuracies.
In addition, identiﬁcation of peptides or proteins was cumber-
some, or not possible at all in these early proﬁling studies.
However, with current equipment these issues can be consid-
ered obsolete. The use of internal standards in combination
with modern mass analyzers now allows precise quantitation
and detailed characterization of peptides in high-throughput
proﬁles [16,17]. Thirdly, similar peptide proﬁles were found
for various diseases, implying that the features were not
speciﬁc. On the other hand, it has been postulated that well-
deﬁned degradation of highly abundant proteins into peptides
(“degradome”) can result in tumor-speciﬁc serum peptidome
patterns [18].
Recently, we reported a protein proﬁling study for PC per-
formed on a fully automated SPE-based serum processing
platform [19]. Proteins were ﬁrst isolated with weak cation
exchange (WCX) magnetic beads (MBs) using a 96-channel
liquid handling robot, followed by acquisition of linear mode
MALDI-TOF proﬁles in the range of 1 to 12kDa, and evaluation
via linear discriminant analysis with double cross-validation.i c s 2 ( 2 0 1 4 ) 39–51
This resulted in a discriminating WCX-proﬁle for PC with a
sensitivity of 78% and a speciﬁcity of 89% in the calibration
set with an area under the curve (AUC) of 90%. These results
were validated with a sensitivity of 74% and a speciﬁcity of
91% (AUC 90%). However, an obvious disadvantage of low res-
olution MS proﬁles is the fact that (poly)peptides and proteins
are measured as broad peaks, thus leading to one of the earlier
mentioned problems on peak identiﬁcation. In a second pro-
ﬁling study using the same PC cohort, serum samples were
processed with reversed-phase (RP) C18 MBs, and resulting
peptides were measured with high resolution reﬂectron mode
MALDI-TOF MS yielding isotopically resolved proﬁles up to
4kDa. For statistical evaluation, a list of 42 different peptides
was compiled from which a discriminating proﬁle for PC could
be deﬁned, with an area under the curve (AUC) of 92% (98%)
a sensitivity of 76% (95%) and speciﬁcity of 91% (100%) in
the calibration (validation) set. Although the identity of most
of these peptides was known or elucidated, it became clear
that multiple peptides still overlapped at the resolving power
of approximately 11,000 [20]. The effect of increased resolv-
ing power was therefore further studied in MALDI-proﬁles
obtained by Fourier transform ion cyclotron resonance (FTICR)
MS, a platform that has proven to be extremely powerful for
the analysis of complex mixtures, such as oil, organic mat-
ter and plasma [21–23]. With proper control, mass resolving
powers higher than 100,000 (at m/z-value 1000 with 1 s tran-
sient) and low or sub-ppm mass measurement errors can be
routinely obtained [24,25]. We have previously developed a
MALDI-FTICR workﬂow on a commercially available platform
equipped with a 15T magnet that allows high-throughput
and fully automated proﬁling of human serum peptides and
proteinswith isotopic resolution up to 15,000Da [26,27]. By fol-
lowing this approach, in comparison to high resolution TOF
analyzers the spectrum alignment is more accurate and the
quantiﬁcation of peptides more robust due to the improved
mass measurement precision. In this study this MALDI-FTICR
workﬂow in combination with SPE-based sample cleanup
with RPC18-functionalized MBs was applied for the analy-
sis of a clinical cohort. Here, “next-generation” MALDI-FTICR
peptide and protein proﬁles were generated using serum sam-
ples obtained from PC patients and control individuals (258
samples in total). Classiﬁcation performances of both the
calibration and validation set were compared to those pre-
viously obtained from the same PC cohort, either processed
with different MBs or measured on a different mass ana-
lyzer. Discriminating peaks (i.e. a biomarker signature) deﬁned
from the calibration set were validated using an indepen-
dent case–control group. Finally, the low ppm mass accuracy
provided by the MALDI-FTICR platform narrows the search
window for de novo identiﬁcations of peptides and proteins in
the proﬁles.
2. Materials and methods
2.1. Patients and sample collectionFor the calibration set, serum samples were obtained from
49 patients with PC prior to surgery, and from 110 (age- and
gender-matched) healthy volunteers (“controls”) over a time
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eriod ranging from October 2002 until December 2008 at
he outpatient clinic of the Leiden University Medical Center
LUMC), the Netherlands. Healthy volunteers were partners
r accompanying persons of included patients. For the vali-
ation set, serum samples were obtained from 39 patients
nd 75 healthy (age- and gender-matched) volunteers over a
ime period ranging from January 2009 until July 2010. Patients
ere selected candidates for curative surgery, thus no patients
ith primary irresectable tumors were included. All surgical
pecimens were examined according to routine histological
valuation and the extent of the tumor spread was assessed
y TNM (TNM Classiﬁcation of Malignant Tumors) classi-
cation. Informed consent was obtained from all subjects
nd the study was approved by the Medical Ethical Commit-
ee of the LUMC. All samples were collected and processed
ccording to a previously reported standardized protocol [9].
rieﬂy, blood samples were drawn by antecubital venipunc-
ure while the individuals, who had not been fasting prior
o any invasive procedure, were seated. The samples were
ollected in an 8.5-cc Serum Separator Vacutainer Tube (BD
iagnostics, Plymouth, UK) and maximally within 4h at room
emperature were centrifuged at 1000× g for 10min. Serum
amples were then distributed into sterile 500-L barcode
abeled polypropylene aliquots (TrakMate; Matrix TechCorp.)
nd stored at −80 ◦C. All serum samples were thawed on
ce once and randomly placed in barcode labeled racks in
n 8-channel Hamilton STAR® pipetting robot (Hamilton) for
utomated aliquotting into 60-L daughter tubes. The aliquots
ere stored in 96-tubes racks at −80 ◦C until further sample
rocessing. Samples from the calibration and the validation
et were distributed over three 96-tubes racks as following:
ne full 96-tube rack for both the calibration and validation
et and one partially ﬁlled 96-tube rack with 63 samples from
he calibration set and 18 samples from the validation set.
dentical processing steps were followed for the two sample
ets.
.2. High-throughput RPC18-MB chromatography and
ALDI spotting
he isolation of peptides from human serum was performed
sing RPC18-functionalized MBs as previously described
27]. In short, RPC18-MBs were ﬁrst activated by a three-step
ashing with a 0.1% TFA solution. Then, for each sample 5L
f serum was added to the activated beads and incubated
or 5min at room temperature. The beads were washed
gain three times with 0.1% TFA and peptides were eluted
ith a 1:1 mixture of water and acetonitrile. Two microliters
f each (stabilized) eluate were mixed with 10L of an -
yano-4-hydroxycinnamic acid MALDI matrix solution in a
84-well PCR plate. Then, 1L of this mixture was spotted in
uadruplicate onto a 600m Anchor-ChipTM MALDI-target
late (Bruker Daltonics). The so-called RPC18 eluates from
he calibration and the validation set were spotted onto three
84-spots MALDI-target plate as following: 96 eluates from
he calibration set and 96 eluates from the validation set
ere spotted in quadruplicate onto two distinct MALDI-target
lates; the remaining eluates from the two sets were spotted
n quadruplicate onto the same MALDI-target plate. Thiscs 2 ( 2 0 1 4 ) 39–51 41
SPE- and MALDI-spotting procedure requires approximately
3h per plate of 96 samples.
2.3. MALDI-FTICR mass spectrometry and data
processing
MALDI-FTICR experiments were performed on a Bruker 15
tesla solariXTM FTICR mass spectrometer equipped with a
novel CombiSource (Bruker Daltonics). The MALDI-FTICR sys-
tem was controlled by Compass solariXcontrol software and
equipped with a Bruker Smartbeam-IITM laser system that
operated at a frequency of 200Hz. The ‘medium’ predeﬁned
shot pattern was used for the irradiation. Two acquisition sett-
ings, namely low-mass method (LM) and high-mass method
(HM), respectively, were used to optimize both the sensitivity
and resolving power in the mass range from 1013 to 3700Da
and in the mass range from 3500 to 10,000Da, respectively.
These methods were optimized as previously described with
some modiﬁcation [27]. For both methods, each mass spec-
trum was obtained from the sum of 10 scans of 150 laser
shots each and using 512K data points. Typically, the target
plate offset was 100V with the deﬂector plate set at 180V.
The ion funnels operated at 100V and 6.0V, respectively, with
the skimmers at 15 and 5V. The analyzer entrance was main-
tained at −7V, and side kick technology was used to further
optimize peak shape and signal intensity. The two acquisi-
tion settings differentiate for the trapping potentials (LM, 0.6
and 0.55V; HM, 0.95 and 0.80V), the required excitation power
(LM, 25%; HM, 28%) and pulse time (LM, 10s; HM, 20s),
the time of ﬂight to the ICR cell (LM, 1.350ms; HM, 2.700ms)
and the quadrupole ﬁlter mass (LM, m/z 1300; HM, m/z 2500).
For each spotted sample, two duplicate spots were measured
using the LM and the other two using the HM. Approximately
4.5h were needed to measure 384 MALDI spots (i.e. originat-
ing from 96 different serum samples). DataAnalysis Software
4.0 SP 5 (Bruker Daltonics) was used for the visualization and
the calibration of the spectra. Prior to the measurement of
each MALDI plate the FTICR system was externally calibrated
using a commercially available peptide mix and a protein
mix (Bruker Daltonics). The spectra obtained using the LM
were internally calibrated only when used for identiﬁcation
purposes. The m/z-values used for the internal calibration of
the LM and the HM are reported in Table S1 in the Supple-
mentary Material. Peaks were determined using the FTMS
algorithm with a signal-to-noise threshold of 3 and using
the centroid for peak position with a percentage height of
80.
Supplementary material related to this article can
be found, in the online version, at doi:10.1016/j.trprot.
2013.12.003.
2.4. Peak selection and quantiﬁcation
Protein and/or peptide signals in RPC18 proﬁles were quanti-
ﬁed as follows. First, based on visual inspection of the proﬁles,
457 and 670 peaks were selected for the LM and HM spectra,
respectively, for further analysis. To this end, a so-called ref-
erence ﬁle was compiled for both types of proﬁles in such a
way that for each selected peak the m/z-value, a peak num-
ber and an m/z-window were reported. In the LM proﬁles, this
teom42 translat ional pro
m/z-window ranged from 0.015 to 0.166Da while in the HM it
ranged from 0.05 to 0.31Da reﬂecting the peak width along the
spectra. Then, the in-house developed Xtractor tool was used
to determine the intensity of each user-deﬁned peak. This
open source tool generates uniform data (peak) arrays regard-
less of spectral content (http://www.msutils.org/Xtractor).
MALDI-FTICR proﬁles were exported as XY (.xy) ﬁles, all con-
taining m/z values with corresponding intensities. Although
peptide and proteins were measured up to 10,000Da using the
HM method, the peak selection was limited to 9043.3Da. The
analysis of the spectra in the m/z-range from 9043.3 to 10,000
is on-going and the results will be presented in a separate
study.
2.5. Statistical analysis
Peak intensities were transformed using the logarithmic func-
tion, followed by calculation of the mean of peak intensities
obtained from replicate spectra. The intensities of isotope
peaks belonging to the same peptide were further summed
to reduce the number of features and time needed for fur-
ther analysis. For each sample, 196 and 291 peak intensity
values were obtained for the LM and HM, respectively, and
wereused to statistical analysis. To this end, logistic regression
ridge shrinkage (LRRS) analysis was applied to the calibra-
tion sets (i.e. LM and HM data from the calibration set) in
order to calibrate two diagnostic rules for the classiﬁcation
of the serum sample either as case or control. Each sam-
ple was assigned to the group for which the probability was
higher. The prediction rules obtained from the application of
LRRS on the calibration sets were applied to the validation
sets (i.e. LM and HM data from the validation set). Thus, each
sample was classiﬁed and the results were compared with
knowndisease status. The classiﬁcationprobabilities assigned
to each sample using the LM and HM data from the validation
set were further combined. To this end, LRRS analysis was
performed on the combination of the logit transformed proba-
bilities obtained for validation sets. This analysis involves the
recalibration of the validated diagnostic rule. For each analysis
error rate (error = the amount by which an observation differs
from its expected value), sensitivity, speciﬁcity and area under
the curve (AUC) were calculated. The error rates are based on
the sensitivity and speciﬁcity values, assuming a prior class
probability of 0.5 for each group. Receiver-operating character-
istic (ROC) curves with the true-positive rate (sensitivity) were
plotted in function of the false-positive rate (1-speciﬁcity) for
different cut-off points of a parameter. Each point on the ROC
curve represents a sensitivity/speciﬁcity pair corresponding to
a particular decision threshold. The area under the ROC curve
(AUC) is a measure of how well a parameter can distinguish
between groups (diseased/healthy). Univariate discriminate
analysis was performed to determine which peak varied the
most between case and control groups. This study was limited
to peaks of which the absolute weighted discriminant coef-
ﬁcient was higher than 0.1 in the multivariate discriminant
analysis used to calibrate the discriminant models. Finally, a
t-testwas performed on a selection of peaks for the calibration
sets only.i c s 2 ( 2 0 1 4 ) 39–51
3. Results
3.1. MALDI-FTICR-MS peptide and protein proﬁling
Serum samples of PC patients as well as control individuals
were processed simultaneously using a previously described
fully automated and standardized SPE-based RPC18-MBproto-
col [15]. Thus obtained MB eluates were spotted onto a MALDI
target plate in quadruplicate. Two types of ultrahigh resolution
peptide and protein proﬁles were then acquired applying an
automated acquisition procedure on the MALDI-FTICR system
(see Section 2). Two out of four spots were used to obtain a so-
called lowmass (LM) proﬁle (m/z-values from1013 to 3700) and
the remaining two spotswereused to generate a so-calledhigh
mass (HM) proﬁle (m/z-values from3500 to 10,000). In total, 273
serum samples were analyzed in this way, thus yielding 1092
proﬁles.A typical example of bothanLMandHMMALDI-FTICR
proﬁle is depicted in Fig. 1A. It was veriﬁed that all peptides
and (small) proteins were measured with isotopic resolution
through all the spectra, with typical resolving powers vary-
ing from 130,000 (m/z 1039.6727) to 46,000 (m/z 3523.7664) in
the LM spectra and from 150,000 (m/z 3680.8709) to 33,000 (m/z
9744.6054) in the HM spectra (as plotted in Fig. 2A). As a result,
a large number of peptides or proteins that would overlap in
high resolution MALDI-TOF MS were measured as distinct fea-
tures by MALDI-FTICR MS. Two examples of resolved species
are shown in Fig. 2B, one for the LMandone for theHMproﬁles.
The ultrahigh resolving power allowed the accurate quantiﬁ-
cation of the selected peptides and proteins in all the spectra.
After manual inspection of the proﬁles, 457 and 670 peaks for
the LM and HM, respectively, were selected for statistical anal-
ysis. After taking into account isotopic peaks from the same
species, 196 peptides remained from the 457 selected peaks
in LM spectra and 291 peptides or proteins remained from the
670 selected peaks in HM spectra. Peptides and proteins were
detected with signal intensities that typically ranged over two
orders of magnitude. For example, Fibrinopeptide alpha chain
(2–16) (at m/z-value 1465.6554) was often observed as the most
intense peptide, and was 304 times more intense than Com-
plement C4-A (1337–1350) (at m/z-value 1626.8459) detected
with a signal-to-noise ratio (S/N) of 6.6, in a typical spectrum.
Thus, peptides observed with low S/N were also evaluated. For
example, the peptide identiﬁed as oxidized Fibrinogen beta
chain (45–71) (m/z 2898.5334) (see Section 3.3) was observed in
the spectra in the calibration set with an averaged S/N 9.6 with
a standard deviation (SD) of 6.4, while the highly intense Com-
plement C3f fragment peptide (at m/z-value 2021.1039) was
observed with an averaged S/N of 2035 with an SD of 345. As
a ﬁnal remark, from 12 out of 1032 proﬁles the quality was
insufﬁcient for further statistical analysis, most likely because
of failed MALDI spotting.
3.2. Statistical analysis
The signal intensities of all selected peaks were determined
in all serum proﬁles using the Xtractor tool described in the
Materials and methods section. As shown in Fig. 2A, the
m/z-windows in the reference ﬁles were ﬁne-tuned accord-
ing to the resolving power calculated for each m/z-value. The
translat ional proteomics 2 ( 2 0 1 4 ) 39–51 43
Fig. 1 – Ultrahigh resolution 15T MALDI-FTICR peptide and protein proﬁles obtained from human serum after RPC18
magnetic bead-based SPE (upper panel). Using two different acquisition settings, optimized for the low-mass and
high-mass range, peptides and proteins were isotopically resolved up to 10kDa. For statistical analysis, logistic regression
ridge shrinkage analysis was used to ﬁnd changes in the peptide and protein proﬁles obtained from healthy individuals
and pancreatic cancer patients. A weighted discriminant coefﬁcient was assigned to each detected peptide or protein
according to its discriminant property in the way that the higher the value of the discriminant coefﬁcient the higher the
case probability (middle panel). Identiﬁcations of the most discriminating peptides and proteins were based on previously
reported peptide IDs or on accurate mass measurement of mass differences in the spectra (lower panel). Note that these
identiﬁcations need further conﬁrmation by MS/MS-data.
44 translat ional proteomics 2 ( 2 0 1 4 ) 39–51
Fig. 2 – For each isotopically resolved peptide or protein signal a speciﬁc m/z-window was deﬁned to allow accurate
quantiﬁcation. The m/z-window was based on the resolving power at a speciﬁc m/z-value (A) and in the case of overlapping
species further optimized (B). Note that the resolving power at m/z 3500 is higher in the high-mass measurements (i.e.
∼150,000) than in the low-mass measurements (i.e. ∼46,000) as a result of the speciﬁc broadband frequency-sweep
waveform that was used to excite the ions into the ICR cell.
presence of different peptides with close masses was also
taken into account aswell as themassmeasurement precision
(see Fig. 2B). The optimization of this m/z-window allowed the
accurate quantiﬁcation of all peaks selected from the spec-
tra. Thus obtained peak intensity values were then used for
statistical analysis. To this end, a discriminate model was
ﬁrst calibrated and then validated using LRRS analysis on the
calibration and validation sets, respectively. The ROC curves
resulted from this analysis are shown in Fig. 3. Error rates of
0.136 and 0.104, sensitivities of 88% and 91% and speciﬁcities
of 96% and 94% with AUC of 0.987 and 0.980 were obtained
for the LM and HM validation sets, respectively. The LRRS
analysis performed on the combination of the logit of the clas-
siﬁcation probabilities obtained for the LM and HM validation
sets resulted in an error of 0.0784, a sensitivity of 89% and
a speciﬁcity of 100% with an AUC of 0.989. The logit trans-
formation involves a recalibration of the discriminant models
obtained using the validation sets. The discriminant analy-
sis performed on the recalibrated validation sets resulted in
errors of 0.098 and 0.088, sensitivities of 88% and 90% andspeciﬁcities of 96% and 93%withAUCof 0.987 and 0.977 for the
LM and HM validation sets, respectively. A sequential analysis
was performed by sub-typing the PC cases into cases with-
out any metastasis (i.e. regional lymph node-negative (LN−)
andno distantmetastasis (DM−)) versus cases thatwere lymph
node-positives (LN+) and/or showed distant metastasis (DM+),
based on TNM-classiﬁcation summarized in Table 1. This sub-
typing resulted in a box plot (see Fig. 3) with clear separation
between controls and cases, and in addition good separa-
tion between cases with and without metastasis (Wilcoxon
Mann–Whitney test with a p-value of 7.7293e−05 for con-
trols versus “(LN−)and(DM−)”, and a p-value of 0.015844 for
“(LN+)and/or(DM+)” versus “(LN−)and(DM−)”).
Patient characteristics, number of serum samples, and
the results of the classiﬁcation methods set are shown in
Table 1. A logistic regression coefﬁcient weighted by the
standard deviation of the peak intensity was assigned to each
peak as determined from multivariate analysis on the cal-
ibration set (i.e. the calibration of the discriminating rule).
These discriminant weights denote the conditional effect
translat ional proteomics 2 ( 2 0 1 4 ) 39–51 45
Fig. 3 – Receiver Operating Characteristic (ROC) curves generated from the case–control classiﬁcation of the serum samples
from both the calibration sets and the validation sets using low-mass (LM) and high-mass (HM) data (four upper panels).
The larger the area under the ROC curve (AUC), the better two groups (diseased/healthy) can be distinguished. The lower
panel on the left hand-side shows ROC curves generated from the combination of the classiﬁcation results obtained from
the validation set. This combination involved the recalibration of the validated diagnostic rules, resulting in recalibrated LM
and HM data. The lower panel on the right hand-side shows box plots that are obtained after sub-typing the PC cases into
cases without any metastasis (i.e. regional lymph node-negatives (LN−) and no distant metastasis (DM−)) versus lymph
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code-positives (LN ) and/or distant metastasis (DM ) based
ssociated with each peak, after taking into account the vari-
tion in expression across the other selected peaks. Thus,
he higher the value of the discriminant weight the higher
he case probability. Note that the reverse applies to control
amples. The plots with the weighted discriminant coefﬁ-
ients versus the m/z-values are shown in Fig. 1B. A t-test
as performed on peaks with absolute discriminant coefﬁ-
ient higher than 0.1 in the calibration set. A p-value smaller
han 0.001 was considered as signiﬁcant. Peaks that satisﬁed
hese criteria are reported in Table 3 with corresponding pro-
tein names, t-test values, standard deviations (SD), p-values,
95%-conﬁdence interval and the weighted discriminant coef-
ﬁcients. Note that the p-values here reported ranged from
6.0× 10−4 to 4.0× 10−9 indicating a high statistical signiﬁ-
ance.NM-classiﬁcation.
3.3. Serum peptide identiﬁcation by accurate mass
difference measurement
A list of serum peptides and proteins that are commonly
observed in MALDI-TOF proﬁles obtained after RPC18-based
sample cleanup has been compiled previously and this was
used for statistical evaluations [9]. However, a number of
peptides remained unidentiﬁed in this list, and moreover in
the current MALDI-FTICR ultrahigh resolution proﬁles many
RPC18-MB serum eluate peaks are unknown. Likely, a large
number of these degradome peptides originate from the
same high abundant proteins after proteolytic cleavage as
was reported earlier [18,28,29]. New peptide assignments
were performed based on matching accurate mass measure-
ments of m/z-differences between peaks in 15T MALDI-FTICR
46 translat ional proteomics 2 ( 2 0 1 4 ) 39–51
Table 1 – Patient characteristics for the calibration and validation sets.
Calibration set Validation set
HM [correct
classif.]
LM [correct
classif.]
Combination
HM and LM
HM [correct
classif.]
LM [correct
classif.]
Combination
HM and LM
No. of samples 46 45 39 35
Age median (min–max) 65.6 (41–80) 65.2 (41–80) 63.4 (38–81) 62.8 (38–81)
Male 23 [16] 22 [17] 16 17 [15] 15 [11] 12
Female 23 [15] 23 [15] 17 22 [17] 20 [15] 15
Localization (pancreas)
Head 38 [28] 36 [27] 33 35 [28] 31 [22] 23
Body 3 [1] 3 [2] 1 1 [1] 1 [1] 1
Tail 3 [1] 4 [2] 2 1 [1] 1 [1] 1
Unknown/other 2 [1] 2 [1] 1 2 [2] 2 [2] 2
Stage
IA 7 [7] 7 [6] 7 2 [1] 2 [0] 0
IB 5 [3] 5 [3] 3 2 [2] 1 [1] 1
IIA 3 [2] 3 [1] 2 3 [1] 3 [0] 1
IIB 19 [13] 17 [14] 13 21 [18] 20 [17] 17
III 5 [3] 5 [4] 3 2 [2] 2 [2] 2
IV 7 [3] 8 [4] 5 9 [8] 7 [6] 6
Tumor differentation
Unknown (irresectable tumor) 12 [7] 11 [6] 7 11 [10] 10 [9] 9
Grade 1 10 [5] 11 [5]
Grade 2 11 [9] 11 [9]
Grade 3 13 [10] 12 [12]
spectra with possible decreased or increased sequences
(“degradome”). Thus, a search for consecutive mass dif-
ferences corresponding to one amino acid was performed,
starting from a previously identiﬁed peptide in the spec-
trum with relatively highest signal intensity. In this way, new
peptides with one or more additional amino acids at the
N-terminus or/and the C-terminus or modiﬁed peptides (i.e.
oxidized, cysteinylated) were identiﬁed. Following this strat-
egy the amino acid sequence of 34 new peptides was derived
and these are reported in Table 2. In general, the LM and
HM proﬁles provided sub- and low-ppm mass measurement
errors for these identiﬁcations, respectively. Two examples
of this approach are shown in Fig. 1C. The ﬁrst one is the
identiﬁcation of an oxidized form of the peptide Fibrinogen
alpha chain (576–604) that was statistically evaluated with a
discriminant weight factor of −0.59 (see Table 3). In the sec-
ond example the accurate mass-based identiﬁcation of the
species observed at m/z-value 4051.9255 is depicted, a peptide
that was found to be the best predictor (i.e. highest abso-
lute discriminant weight) of healthy and disease individuals
in HM proﬁles (see Table 3). The mass difference between
this peptide and a peptide previously MS/MS-identiﬁed as
cysteinylated-Prothrombin (328–363), observed at m/z-value
4208.0269, was 156.1014Da. This mass difference corresponds
to an arginine residue with an error of only 0.3mDa. In addi-
tion, the accurate measurement of mass differences allowed
the identiﬁcation of peptides containing a single amino acid
mutation. For example, a peptide from coagulation factor XIII
(Factor XIIIa) alpha chain with a previously reported Val35Leu
mutation corresponding to a mass difference of 14.0156Da
between “normal” and mutant fragment peptides was indeed
observed (see Table 2). Here, the species atm/z-value 2602.3113
corresponds to a previously identiﬁed peptide from Factor
XIIIa (14–38), whereas the species at m/z-value 2531.2735 and6 6 [2] 6 [3] 3
9 15 [14] 13 [10] 10
11 7 [6] 6 [4] 5
m/z-value 2545.2883 both lack an alanine residue but dif-
fer at the site of mutation (i.e. Val35 Factor XIIIa (15–38)
and Leu35 Factor XIIIa (15–38), respectively). It is empha-
sized that isobaric peptides containing modiﬁcations such
as oxidation cannot be uniquely characterized by the accu-
rate measurement of mass differences. For this purpose
additional MS/MS-experiments are needed to conﬁrm the
identiﬁcations and localize for instance modiﬁed amino acids
in the sequence. As a ﬁnal remark, the accurate and pre-
cise MALDI-FTICR mass measurements will allow a reliable
match between theMS/MS-data obtainedusing otherMS tech-
niques such as LC-ESI-MS/MSand the peptides observed in the
MALDI-FTICR spectra.
4. Discussion
The past decade, MS-based proﬁling studies have been carried
out to determinedisease-speciﬁc serumpeptidomesignatures
in a “case–control” setting. Due to the relatively high bio-
logical variability of the serum peptidome (and proteome) a
largenumber of samples are required for statistical evaluation.
Thus, high-throughput analytical methodologies have been
adopted in combination with MS, pioneered by SELDI-TOF
platforms. In the same period, high-throughput robotic plat-
forms with more ﬂexible and user-deﬁned sample preparation
protocols were combined with MALDI-TOF read-out. Both
low-resolution TOF-proﬁles with a wide m/z-range and high-
resolution proﬁles with smaller m/z-windows were reported
for proteins and peptides, respectively [7,30,31]. However,
single- or even multi-step protein fractionations still yield
highly complex samples and the low resolving powers in
linear mode SELDI- or MALDI-TOF proﬁles do not allow accu-
rate quantiﬁcation of the proﬁled species. Peptides up to
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Table 2 – Proposed sequences of (large) peptides present in MALDI-FTICR precision proﬁles based on accurate mass measurements.
Protein name Peptide sequencea Mass difference Calculated m/z
[M+H]+
Observed m/z
[M+H]+
Mass measur.
error (ppm)
MALDI-FTICR
method
ITIH4 UniProt
Q14624
M.NFRPGVLSSRQLGLPGPPDVPDHAAYHPF.R +(NRF+0.0033) 3141.6017 3141.6047 0.96 LM
N.FRPGVLSSRQLGLPGPPDVPDHAAYHPF.R +(RF+0.0009) 3027.5588 3027.5593 0.18 LM
R.PGVLSSRQLGLPGPPDVPDHAAYHPFR or
RPGVLSSRQLGLPGPPDVPDHAAYHPF.R
+(R− 0.0004) 2880.4904 2880.4896 −0.26 LM
R.PGVLSSRQLGLPGPPDVPDHAAYHPF.R – 2724.3893 2724.3889 −0.13 LM
P.GVLSSRQLGLPGPPDVPDHAAYHPF.R −(P + 0.0002) 2627.3365 2627.3360 −0.19 LM
Thrombin light
chain UniProt P00734
L.FEKKSLEDKTERELLESYIDGR +(FEKK− 0.0011) 2685.3730 2685.3720 −0.36 LM
F.EKKSLEDKTERELLESYIDGR +(EKK− 0.0008) 2538.3046 2538.3039 −0.28 LM
E.KKSLEDKTERELLESYIDGR +(KK− 0.0005) 2409.2620 2409.2615 −0.19 LM
K.KSLEDKTERELLESYIDGR +(K+0.0004) 2281.1670 2281.1676 0.23 LM
K.SLEDKTERELLESYIDGR – 2153.0721 2153.0722 0.04 LM
S.LEDKTERELLESYIDGR −(S + 0.0012) 2066.0400 2066.0390 −0.53 LM
L.EDKTERELLESYIDGR −(SL + 0.0001) 1952.9560 1952.9560 0.02 LM
E.DKTERELLESYIDGR −(SLE+0.0010) 1823.9134 1823.9124 −0.52 LM
D.KTERELLESYIDGR −(SLED+0.0001) 1708.8864 1708.8865 0.01 LM
Thrombin light
chain UniProt P00734
TFGSGEADC(CysGly)GLRPLFEKKSL
EDKTERELLESYIDG
+(G+0.0032) 4265.0489 4265.0520 0.73 HM
TFGSGEADC(Cys)GLRPLFEKKSLEDKTEREL
LESYIDGR
– 4208.0275 4208.0274 −0.02 HM
TFGSGEADC(CysGly)GLRPLFEKKSLED
KTERELLESYIDG
−(R-Gly− 0.0001) 4108.9478 4108.9479 0.02 HM
TFGSGEADCGLRPLFEKKSLEDKT
ERELLESYIDGR
−(Cysteinylation+0.0010) 4089.0234 4089.0222 −0.27 HM
TFGSGEADC(Cys)GLRPLFEKKSLEDKTER
ELLESYIDG
−(R− 0.0034) 4051.9263 4051.9297 0.82 HM
TFGSGEADC(CysGly)GLRPLFEKKSLEDK
TERELLESYIDG
+(G+0.0032) 4265.0489 4265.0520 0.73 HM
Fibrinogen alpha
chain UniProt P02671
K.SSSYSKQFTSSTSYNRGDSTFESKSY
KMADEAGSEADHEGTHSTKRGHAKSRPV.R
– 5901.70298 5901.70641 0.58 HM
K.SSSYSKQFTSSTSYNRGDSTFESKSYKMA
DEAGSEADHEGTHSTKRGHAKSRP.V
−(V+0.0010) 5802.63456 5802.6370 0.42 HM
Fibrinogen alpha
chain UniProt P02671
K.SSSYSKQFTSSTSYNRGDSTFESKSYK
MADEAGSEADHEGTHSTKRGHA.K
– 5334.3536 5334.3572 0.67 HM
K.SSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKR.G
−(GHA+0.0002) 5069.2362 5069.2395 0.65 HM
K.SSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTK.R
−(RGHA+0.0099) 4913.1351 4913.1288 −1.28 HM
K.SSSYSKQFTSSTSYNRGDSTFESKSY
KMADEAGSEADHEGTHST.K
−(KRGHA− 0.0005) 4785.0401 4785.0442 0.86 HM
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Table 2 – (Continued)
Protein name Peptide sequencea Mass difference Calculated m/z
[M+H]+
Observed m/z
[M+H]+
Mass measur.
error (ppm)
MALDI-FTICR
method
Platelet Factor 4
UniProt P02776
FASAEAEEDGDLQCLCVKTTSQVRPRHITSLEVI
KAPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
+(FASA+0.0385) 8141.3692 8141.3932 2.94 HM
F.SAEAEEDGDLQCLCVKTTSQVRPRHITSLEV
IKAPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
+(SA− 0.0027) 7923.2636 7923.2464 −2.17 HM
S.AEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAP
HCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
+(A+0.0297) 7836.2316 7836.2468 1.93 HM
A.EAEEDGDLQCLCVKTTSQVRPRHITS
LEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
– 7765.1945 7765.1799 −1.88 HM
E.AEEDGDLQCLCVKTTSQVRPRHITSLEVIKAPHCP
TAQLIATLKNGRKICLDLQAPLYKKIIKKLLES
−(E + 0.0132) 7636.1518 7636.1240 −3.64 HM
A.EEDGDLQCLCVKTTSQVRPRHITSLEVIKAPHCPTAQLIA
TLKNGRKICLDLQAPLYKKIIKKLLES
−(EA+0.068) 7565.1147 7565.0933 −2.83 HM
HMW Kininogen
UniProt P01042
H.NLGHGHKHERDQGHGHQ – 1943.9080 1943.9071 −0.47 LM
HNLGHGHKHERDQGHGHQ +(H+0.0001) 2080.9669 2080.9661 −0.39 LM
Complement C3f
fragment UniProt
P01024
SSKITHRIHWESASLLR – 2021.1039 2021.10398 0.04 LM
S.SKITHRIHWESASLLR −(S + 0.0005) 1934.0719 1934.0715 −0.20 LM
S.KITHRIHWESASLLR −(SS+0.0013) 1847.0399 1847.03869 −0.63 LM
H.RIHWESASLLR −(SSKITH+0.0003) 1367.75424 1367.75405 −0.14 LM
I.HWESASLLR or RIHWESASL.L −(SSKITHRI/L− 0.0005) 1098.56907 1098.56968 0.56 LM
Factor XIIIa UniProt
P00488
R.AVPPNNSNAAEDDLPTVELQGVVPR.G – 2602.3107 2602.3113 0.22 LM
A.VPPNNSNAAEDDLPTVELQGLVPR.G −(A− 14.0141) 2545.2893 2545.2883 −0.38 LM
A.VPPNNSNAAEDDLPTVELQGVVPR.G −(A− 0.0006) 2531.2736 2531.2735 −0.04 LM
a The sequences of previously identiﬁed peptides that are depicted in bold were used as a starting point in ﬁnding consecutive mass differences.
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Table 3 – Peptides present in MALDI-FTICR precision proﬁles with low p-values after comparative analysis of serum
samples from pancreatic cancer patients and control individuals.
Observed m/z [M+H]+ Protein name t-Test SD p-Value CI lower CI upper B-weighted
Low-mass MALDI-FTICR proﬁles
1206.5753 FPA chain (5–16) 3.7 3.4 2.7E−04 1.1 3.5 −0.51
1211.6535 Complement C3f fragment (7–16) −4.0 2.0 1.1E−04 −2.1 −0.7 0.42
1263.5965 FPA chain (4–16) 5.0 3.0 1.3E−06 1.6 3.7 −0.64
1348.7118 Complement C3f fragment (6–16) −3.6 1.5 4.1E−04 −1.5 −0.4 0.16
1350.6282 FPA chain (3–16) 4.4 3.5 2.4E−05 1.5 3.9 −0.56
1449.7597 Complement C3f fragment (5–16) −4.0 3.3 1.1E−04 −3.5 −1.2 0.84
1561.7265 Prothrombin (315–327) 4.5 1.9 1.4E−05 0.8 2.2 −0.25
1616.6584 FPA chain 1P 5.0 3.4 1.8E−06 1.8 4.2 −0.36
1626.8458 Complement C4-A (1337–1350) −3.7 1.1 3.2E−04 −1.1 −0.3 0.15
1698.7450 n.i. −3.5 0.9 6.0E−04 −0.9 −0.3 0.12
1718.9430 Complement C3f fragment (4–16) −4.2 1.6 4.4E−05 −1.7 −0.6 0.39
1786.8545 ITIH4 (671–687) −4.7 1.7 6.5E−06 −2.0 −0.8 0.23
1984.9879 n.i. 3.6 1.2 4.8E−04 0.3 1.2 −0.25
2685.3746 Thrombin light chain (342–363) −5.8 1.1 3.9E−08 −1.5 −0.7 0.18
2768.2293 FGA chain (576–600) 3.9 3.5 1.5E−04 1.2 3.7 −0.79
2898.5334 FGB chain (45–71) + 15.9952Da −6.3 1.3 4.0E−09 −2.0 −1.0 0.32
2931.2909 FGA chain precursor (576–601) 4.9 3.8 2.2E−06 2.0 4.7 −0.70
3190.4279 FGA chain (576–603) 5.9 3.1 2.9E−08 2.1 4.3 −0.76
3206.4243 FGA chain (576–603) [Met-ox] 5.2 2.1 7.1E−07 1.2 2.7 −0.23
3261.4664 FGA chain (576–604) 5.1 3.5 1.3E−06 1.9 4.4 −0.59
High-mass MALDI-FTICR proﬁles
3679.8665 n.i. −4.3 0.7 3.7E−05 −0.8 −0.3 0.14
3806.8902 n.i. −4.2 0.7 5.4E−05 −0.7 −0.3 0.19
4051.9297 Thrombin light chain (328–363)
(cysteinylated)
−5.8 2.8 4.4E−08 −3.8 −1.9 1.72
4108.9479 Thrombin light chain (328–363)
(cysteinylated+Gly)
−4.6 1.5 7.6E−06 −1.8 −0.7 0.24
4394.0803 n.i. 3.8 1.6 2.1E−04 0.5 1.7 −0.62
4854.2768 Apolipoprotein CIII2 (21–99)a −3.9 2.5 1.7E−04 −2.6 −0.8 0.28
4961.4906 FGA chain (529–574) or (513–558) −4.5 2.9 1.3E−05 −3.3 −1.3 1.16
4979.4945 FGA chain (529–574) or
(513–558) + 15.9952Da
−5.0 2.1 1.7E−06 −2.6 −1.1 0.36
4985.4806 n.i. −3.7 1.7 2.9E−04 −1.7 −0.5 −0.30
5802.6370 FGA chain (576–627) −3.7 3.2 2.7E−04 −3.2 −1.0 0.62
6223.3096 n.i. −4.5 1.4 1.2E−05 −1.6 −0.6 0.19
7151.4191 n.i. −3.5 1.6 5.9E−04 −1.5 −0.4 0.11
8205.0930 Apolipoprotein CII (23–101) −3.8 1.8 2.4E−04 −1.9 −0.6 0.88
8781.2819 Apolipoprotein-CIII 3.8 2.8 1.8E−04 0.9 2.9 −1.19
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a This species was observed as a doubly charged ion.
/z-values of 4500 can be routinely analyzed with isotopic
esolution using TOF-analysers in reﬂectron mode, but at the
ost of restricting the analyzed m/z-range and thus exclud-
ng proteins from the evaluation. Moreover, reﬂectron mode
roﬁles still contain a signiﬁcant number of overlapping pep-
ides, as we previously demonstrated in ultrahigh resolution
ALDI-FTICR proﬁles [20].
In this study the ultrahigh resolving power provided by
15T MALDI-FTICR system was exploited in terms of dis-
riminative power of case–control peptidome proﬁles and
dentiﬁcation of observed species. This is the ﬁrst proﬁling
tudy that reports on the application of such ultrahigh res-
lution proﬁles exempliﬁed by a clinical cohort of serum
amples from healthy individuals and PC patients. Aiming for
ancer-speciﬁc peptide and protein signatures, these serum
amples were ﬁrst fractionated on a fully automated SPE-
latform based on functionalized MBs and then proﬁled using
15T MALDI-FTICR mass spectrometer. In total, 487 peptidesor small proteins (i.e. 196 and 291 in LM and HM spectra,
respectively) were measured with isotopic resolution in the
m/z-range 1–9kDa and quantiﬁed with high accuracy and
precision. The ultrahigh resolving power allowed the correct
quantiﬁcation of peptides or proteins that previously were
observed to suffer from overlapping isotopic distributions in
lower resolution proﬁles (see Fig. 2). Note that the total num-
ber of detectable peptides was higher, i.e. several peptides
were detected only in few particular samples, probably due
to a higher expression of a particular protein or an elevated
protease activity.
Two different MALDI-FTICR acquisition methods, namely
a low mass and a high mass method, were used to gener-
ate peptide and protein proﬁles from two independent groups
of serum samples. A calibrated and validated discriminating
rule built on the combination of the data obtained from the
two MALDI-FTICR methods resulted in a sensitivity of 89%
and a speciﬁcity of 100% with an AUC of 0.989. These results
teom
r50 translat ional pro
corroborate classiﬁcation numbers from our previous MALDI-
TOF studies [19,32]. The t-test analysis performed on the
peptides with absolute discriminant weights higher than 0.1
resulted in the identiﬁcation of 34 peptides that (i.e. p-value
lower than 0.001) differentiate between case and control
groups (see Table 3). The high precision and accuracy of the
mass measurements allowed the identiﬁcation of 26 of these
peptides either by comparison with previously reported pep-
tides or by accurate mass measurement of mass differences in
the spectra (see Section 2). Application of the latter approach
resulted in the identiﬁcation of peptides generated through
proteolysis of the same protein. In fact, starting from a previ-
ously identiﬁed peak (i.e. peptide) it was found that accurate
measurement of the difference between that speciﬁc m/z-
value and the m/z-value of a new peak matched to a similar
peptidewith either one amino acidmore or less at theC- or the
N-terminus, corresponding to the “overall” protein sequence.
Thus, up to 8 new peptides could be identiﬁed starting from
the fragment peptide K.SLEDKTERELLESYIDGR of thrombin
light chain (UniProt P00734) (see Table 2). Nevertheless, the
presence of isobaric peptides cannot be excluded and MS/MS
experiments are required to further validate the identiﬁca-
tions. In conclusion, using the two identiﬁcation approaches
described above, we are now able to further expand the total
number of identiﬁed peptides, especially at higher m/z-values.
Other MALDI-proﬁling methods that so far have been used for
the characterization of human serum peptides were not suit-
able for the identiﬁcation of highmolecularweight peptides or
proteins, because these lacked sensitivity and resolving power
[28,29].
As a ﬁnal remark, it should be noted that at this stage
the peptidome proﬁles were not evaluated for the m/z-range
from 9000 to 10,000. Here, both the high density of peaks
and the relatively lower resolving power do not permit bin-
ning of the data points. The most abundant peaks present
in this range were identiﬁed as apolipoprotein-CIII isoforms
[26] and these data will be evaluated in a separate study
using a different quantiﬁcation method. In this study, we
have shown that high quality human serum peptide and
protein proﬁles can be generated using a standardized and
robust protocol for the sample preparation and ultrahigh res-
olution 15T MALDI-FTICR MS for the mass measurements.
The use of this mass analyzer allowed the isotopic reso-
lution and the accurate and precise mass measurement of
a high number of peptides and small proteins in a wide
m/z-range. Notably, recent innovation in ICR-cell technology
potentially provides similar performance at a lower mag-
netic ﬁeld strength [33]. The statistical analysis of proﬁles
generated from a clinical cohort of samples allowed the dis-
crimination between healthy individuals and PC patients with
sensitivity and speciﬁcity comparable with those reported by
other authors using MALDI-TOF MS. A total of 273 serum
samples was processed and mass analyzed within a time
frame of 24h and the high quality of the data both facilitated
the interpretation and evaluation of the generated proﬁles.
These ultrahigh resolution mass spectra represent a “next-
generation” of MS-based peptidome proﬁles and provide a
new tool for a more detailed description of the high-abundant
proteins in clinical serumsample cohorts aiming for newdiag-
nostic leads.i c s 2 ( 2 0 1 4 ) 39–51
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